What is Savient Pharmaceuticals Cash Flow from Investing?
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the
three
months ended in Sep. 2013, Savient Pharmaceuticalsspent€0.00 Mil on purchasing property, plant, equipment.
It gained€0.00 Mil from selling property, plant, and equipment.
It spent€0.00 Mil on purchasing business.
It gained€0.00 Mil from selling business.
It spent€-0.04 Mil on purchasing investments.
It gained€5.16 Mil from selling investments.
It paid€0.00Mil for net Intangibles purchase and sale.
And it received€0.58 Mil from other investing activities.
In all, Savient Pharmaceuticalsgained€5.78 Mil on investment activities in financial market and operating subsidiaries for the
three
months ended in Sep. 2013.
Savient Pharmaceuticals Cash Flow from Investing Historical Data
The historical data trend for Savient Pharmaceuticals's Cash Flow from Investing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Savient Pharmaceuticals Cash Flow from Investing Chart
Savient Pharmaceuticals Cash Flow from Investing Calculation
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
Savient Pharmaceuticals's Cash Flow from Investing for the fiscal year that ended in Dec. 2012 is calculated as:
Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €32.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Savient Pharmaceuticals (FRA:BY7) Cash Flow from Investing Explanation
Savient Pharmaceuticals's purchase of property, plant, equipment for the
three
months ended in Sep. 2013 was €0.00 Mil. It means Savient Pharmaceuticals spent €0.00 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Savient Pharmaceuticals's sale of property, plant, equipment for the
three
months ended in Sep. 2013 was €0.00 Mil. It means Savient Pharmaceuticals gained €0.00 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
Savient Pharmaceuticals's purchase of business for the
three
months ended in Sep. 2013 was €0.00 Mil. It means Savient Pharmaceuticals spent €0.00 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
Savient Pharmaceuticals's sale of business for the
three
months ended in Sep. 2013 was €0.00 Mil. It means Savient Pharmaceuticals gained €0.00 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
Savient Pharmaceuticals's purchase of investment for the
three
months ended in Sep. 2013 was €0.04 Mil. It means Savient Pharmaceuticals spent {stock_data.stock.currency_symbol}}-0.04 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
Savient Pharmaceuticals's sale of investment for the
three
months ended in Sep. 2013 was €5.16 Mil. It means Savient Pharmaceuticals gained €5.16 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
Savient Pharmaceuticals's net Intangibles purchase and sale for the
three
months ended in Sep. 2013 was €0.00 Mil.
It means Savient Pharmaceuticals paid €0.00 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
Savient Pharmaceuticals's cash from discontinued investing activities for the
three
months ended in Sep. 2013 was 0.00 Mil.
It means Savient Pharmaceuticals paid €0.00 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
Savient Pharmaceuticals's cash from other investing activities for the
three
months ended in Sep. 2013 was €0.58 Mil.
It means Savient Pharmaceuticals received €0.58 Mil from other investing activities.
Savient Pharmaceuticals Cash Flow from Investing Related Terms
Thank you for viewing the detailed overview of Savient Pharmaceuticals's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.
Savient Pharmaceuticals (FRA:BY7) Business Description
Savient Pharmaceuticals, Inc., was founded in 1980. It develops, manufactures and markets products through the application of genetic engineering and related biotechnologies. The Company, and its wholly-owned Subsidiaries, is a specialty biopharmaceutical company focused on commercializing KRYSTEXXA (pegloticase) in the United States and completing the development and seeking regulatory approval outside of the United States for KRYSTEXXA, particularly in the European Union. It completed a promotional launch of KRYSTEXXA in the United States during the first quarter of 2011 with its sales force commencing field promotion to health care providers on February 28, 2011. The Company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The Company launched its authorized generic version of oxandrolone in December 2006 in response to the approval and launch of generic competition to Oxandrin. On January 1, 2012, KRYSTEXXA received a permanent J Code, which facilitates reimbursement to providers who treat patients suffering with RCG and who rely on Medicare and Medicaid. The manufacturing process for pegloticase, which is the drug substance of KRYSTEXXA, consists of the production through a recombinant process in which a genetically-engineered bacteria produces uricase, followed by its purification, PEGylation, further purification and formulation to produce the bulk pegloticase, which the company refers it as pegloticase drug substance. Pegloticase is aseptically filtered and filled into sterile, single dose vials to produce the KRYSTEXXA drug product. Its sales force targets rheumatologists and nephrologists with access to infusion centers and healthcare institutions, each of which treat adult patients suffering from RCG, as well as podiatrists who also treat patients with RCG. In March 2012, KRYSTEXXA was made available in the EU to healthcare professionals through a Named Patient Program. The Company sells its products to three drug wholesaler customers and various specialty distributors. Its research and development includes costs associated with the research and development of its KRYSTEXXA product prior to FDA approval and FDA-related post-marketing commitments for approved products (KRYSTEXXA post-approval). These costs mainly include pre-clinical and clinical studies and trials, personnel costs including compensation, consultants and contract research organizations, or CROs, quality control and assurance costs, regulatory costs and costs related to the development of commercial scale manufacturing capabilities for KRYSTEXXA, which also includes the costs of preparing Fujifilm to serve as its secondary source supplier of pegloticase drug substance for KRYSTEXXA in the United States. As of March 7, 2013, the company owned 14 issued U.S. patents and 154 issued foreign patents. It currently owns U.S. and several foreign registrations or applicat
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:BY7 has been successfully added to your 